Group L P Ponoi Capital Ii,... Net Worth

The estimated Net Worth of Group L P Ponoi Capital Ii,... is at least $67.8 mil dollars as of 15 May 2019. Group Ii owns over 24,000 units of Ngm Biopharmaceuticals Inc stock worth over $67,760 and over the last 6 years Group sold NGM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Group Ii NGM stock SEC Form 4 insiders trading

Group has made over 1 trades of the Ngm Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Group exercised 24,000 units of NGM stock worth $320,400 on 15 May 2019.

The largest trade Group's ever made was exercising 24,000 units of Ngm Biopharmaceuticals Inc stock on 15 May 2019 worth over $320,400. On average, Group trades about 24,000 units every 0 days since 2019. As of 15 May 2019 Group still owns at least 44,000 units of Ngm Biopharmaceuticals Inc stock.

You can see the complete history of Group Ii stock trades at the bottom of the page.

Insiders trading at Ngm Biopharmaceuticals Inc

Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel y Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.

What does Ngm Biopharmaceuticals Inc do?

ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work

Complete history of Group Ii stock trades at Ngm Biopharmaceuticals Inc

Ngm Biopharmaceuticals Inc executives and stock owners

Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Woodhouse,
  Chief Executive Officer, Director
• Jin-Long Chen,
  Founder, Chief Scientific Officer, Director
• William Rieflin,
  Executive Chairman of the Board of Directors
• Suzanne Hooper,
  Independent Director
• Dr. David J. Woodhouse Ph.D.,
  CEO & Director
• Dr. Jin-Long Chen Ph.D.,
  Founder, Chief Scientific Officer & Director
• Shelly Guyer,
  Independent Director
• Siobhan Nolan Mangini,
  CFO and Principal Financial & Accounting Officer
• McHenry Tichenor,
  Independent Director
• David Goeddel,
  Lead independent director
• David Schnell,
  Independent Director
• Mark Leschly,
  Independent Director
• William J. Rieflin J.D.,
  Exec. Chairman of Directors
• Siobhan Mangini,
  Chief Financial Officer
• Carole Ho,
  Independent Director
• Hsiao Lieu,
  Senior Vice President, Chief Medical Officer
• Marc Learned,
  Vice President - Research Operations
• Hui Tian,
  Senior Vice President - Research
• Wenyan Shen,
  Senior Vice President - Biologics and CMC
• Alex DePaoli,
  Senior Vice President, Chief Translational Officer
• Valerie Pierce,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Hsiao Dee Lieu,
  Chief Medical Officer & Sr. VP
• Brian Muma,
  VP of HR
• Valerie L. Pierce J.D.,
  Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Alexander Duke Schwartz,
  Exec. Director of Investor Relations
• Group L Ptcg Opportunity Ii...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L P Svennilson Peter ...,
  
• Peter Svennilson,
  Director
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Aetna Wun Trombley,
  President & COO
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Ii, L...,
  
• Group L P Ponoi Capital Ii,...,
  
• Group L Pcolumn Group Iii, ...,
  
• Roger M Perlmutter,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Jean Frederic Viret,
  Chief Financial Officer
• Group Gp, Lpcolumn Group Ii...,
  
• Opportunity Iii Gp, Llc Tcg,
  10% owner
• Irene Perlich,
  Principal Accounting Officer